Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-06-19
DOI
10.1038/s41598-017-04147-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells
- (2017) Majid Momeny et al. Scientific Reports
- Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials
- (2016) Taner Korkmaz et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
- (2015) Said A Khelwatty et al. BRITISH JOURNAL OF CANCER
- Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models
- (2015) D. M. Francis et al. CLINICAL CANCER RESEARCH
- Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines
- (2015) Majid Momeny et al. Oncotarget
- Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells
- (2015) Michaela L. Granados et al. PLoS One
- ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
- (2014) Carlos L. Arteaga et al. CANCER CELL
- Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread
- (2014) Sunila Pradeep et al. CANCER CELL
- Treatment of ovarian cancer beyond chemotherapy: Are we hitting the target?
- (2014) Álvaro Henrique Ingles Garces et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- High Incidence of ErbB3, ErbB4, and MET Expression in Ovarian Cancer
- (2014) Suzy Davies et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial
- (2014) Suresh S Ramalingam et al. LANCET ONCOLOGY
- HER2 mediates epidermal growth factor-induced down-regulation of E-cadherin in human ovarian cancer cells
- (2013) Jung-Chien Cheng et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study
- (2013) Ignace B. Vergote et al. JOURNAL OF CLINICAL ONCOLOGY
- Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab
- (2013) Ferdows Ather et al. PLoS One
- FoxM1 mediated resistance to gefitinib in non-smallcell lung cancer cells
- (2012) Nuo Xu et al. ACTA PHARMACOLOGICA SINICA
- A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer
- (2012) S. B. Kaye et al. ANNALS OF ONCOLOGY
- The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer
- (2012) Ting Gui et al. Cancer Epidemiology
- Abstract 2979: Epithelial-mesenchymal gene expression signature defines clinically relevant subtypes in epithelial ovarian cancer
- (2012) Ruby YJ Huang et al. CANCER RESEARCH
- Targeting Pathways Contributing to Epithelial-Mesenchymal Transition (EMT) in Epithelial Ovarian Cancer
- (2012) Ruby Yun-Ju Huang et al. CURRENT DRUG TARGETS
- Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2012) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis
- (2012) Alberto Ocana et al. JNCI-Journal of the National Cancer Institute
- Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
- (2012) O. Kalous et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells
- (2012) Martin Bezler et al. Molecular Oncology
- FOXM1: From cancer initiation to progression and treatment
- (2011) Chuay-Yeng Koo et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells
- (2011) M Comamala et al. BRITISH JOURNAL OF CANCER
- The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer
- (2011) Q Sheng et al. BRITISH JOURNAL OF CANCER
- Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
- (2011) P. A. Janne et al. CLINICAL CANCER RESEARCH
- Acquisition of Chemoresistance and EMT Phenotype Is Linked with Activation of the Endothelin A Receptor Pathway in Ovarian Carcinoma Cells
- (2011) L. Rosano et al. CLINICAL CANCER RESEARCH
- Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells
- (2011) P Yue et al. ONCOGENE
- Ovarian Cancer Development and Metastasis
- (2010) Ernst Lengyel AMERICAN JOURNAL OF PATHOLOGY
- Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells
- (2010) Shilpa Tyagi et al. BIOCHEMICAL PHARMACOLOGY
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2
- (2010) C. M. Annunziata et al. CLINICAL CANCER RESEARCH
- Mechanisms of resistance to HER family targeting antibodies
- (2010) Tim J. Kruser et al. EXPERIMENTAL CELL RESEARCH
- Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment
- (2010) Stephanie V. Blank et al. GYNECOLOGIC ONCOLOGY
- Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicatesZEB2in tumor progression and prognosis
- (2009) Kosuke Yoshihara et al. CANCER SCIENCE
- Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer
- (2009) U. B. McGovern et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges
- (2009) Doris R. Siwak et al. Journal of Oncology
- Anoikis: A necessary death program for anchorage-dependent cells
- (2008) Paola Chiarugi et al. BIOCHEMICAL PHARMACOLOGY
- Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer
- (2008) Jacqueline M. Lafky et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- New therapies for ovarian cancer: Cytotoxics and molecularly targeted agents
- (2008) Phuong Dinh et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Group study
- (2008) Angeles Alvarez Secord et al. GYNECOLOGIC ONCOLOGY
- Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis
- (2008) Ifat Sher et al. INTERNATIONAL JOURNAL OF CANCER
- Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer
- (2008) Gabriella Ferrandina et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
- (2008) A. J. Gonzales et al. MOLECULAR CANCER THERAPEUTICS
- Estrogen Regulates Snail and Slug in the Down-Regulation of E-Cadherin and Induces Metastatic Potential of Ovarian Cancer Cells through Estrogen Receptor α
- (2008) Se-Hyung Park et al. MOLECULAR ENDOCRINOLOGY
- Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression
- (2008) Zheng Fu et al. NATURE CELL BIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started